COMMUNIQUÉS West-GlobeNewswire

Surgery Partners, Inc. Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details
24/02/2026
BRENTWOOD, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
24/02/2026
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating [...]
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
24/02/2026
Results in a population of 278 patients affirm statistically significant mortality reductions Benefits observed across severity groups and in subjects with serious comorbidities Company files provisional patent [...]
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
24/02/2026
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting [...]
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
24/02/2026
Collaboration powers secure international data sharing through the HiFi Solves Global Consortium MENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced [...]
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
24/02/2026
Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate material dilution SAN [...]
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
24/02/2026
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the [...]
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
24/02/2026
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled [...]
Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System
24/02/2026
Early Post-Clearance Momentum Signals Accelerated Hospital Adoption of Advanced Robotics HINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the [...]
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
24/02/2026
GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may [...]
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
24/02/2026
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo [...]
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique
24/02/2026
Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par [...]
Human Continuum Appoints Dr. Michael Milligan, MD, MBA, as its Chief Medical Officer to Oversee Innovative Applications for Next-Generation Extracellular Vesicle Therapeutics
24/02/2026
New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”) , a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has [...]
Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana
24/02/2026
Center to Create Local Jobs and Strengthen U.S. Healthcare Supply Resilience SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing [...]
Respiree Strengthens Series A Syndicate to Advance Next-Generation Cardiorespiratory Care
24/02/2026
HOUSTON and SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Respiree , a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced [...]
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
24/02/2026
Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophy HOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration (FDA) in [...]
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
24/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
24/02/2026
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical- [...]
Dentsply Sirona and Burkhart Dental Supply Announce Expanded Distribution Partnership to Include Dental Technology Equipment
24/02/2026
As of April 1, Burkhart Dental Supply will represent Dentsply Sirona’s full portfolio of dental technology solutions in addition to preventive and restorative solutions it already distributes. The expanded partnership [...]

Pages